Administration of recombinant human leukocyte alpha 2-interferon in patients with amyotrophic lateral sclerosis.
Recombinant leukocyte alpha 2-interferon (with greater than 98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.
D000328:Adult; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008875:Middle Aged
D007370:Interferon Type I